CSL earnings preview: what to watch out for from its FY19 release

Here are some of the key things investors should be aware of ahead of CSL’s full-year earnings, set to be released August 14.

When is CSL’s results date?

The global biotechnology company will release its 2019 full-year results on Wednesday August 14.

CSL full-year results preview

CSL Ltd, the A$99.8 billion biotechnology company has been a strong performer year-to-date, seeing its share price rise 17% since January.

The company’s solid share price momentum has been underpinned by impressive business growth and improved FY19 guidance.

In the first-half of 2019, the biotech giant saw its revenue hit $4.5 billion, an 11% increase year-over-year.

These results were driven by good demand for a number of the company’s cornerstone products, including ‘Immunoglobulin, Specialty Products and Influenza.’

CSL’s stellar top-line growth had a positive knock-on effect on the company’s profitability. Here, CSL saw its earnings after tax and earnings per share (EPS) both grow by 10% in the 2019 first-half.

Investors will likely be keen to see this upward momentum continue when CSL announces their full-year results next week.

Off the back of these strong profits, CSL issued investors a interim dividend of $0.85 cents per share – a 8% increase on the interim dividend from the year prior.

CSL share price outlook in focus

The outlook appears good for the biotechnology giant, with CSL Ltd noting that demand remains robust for its core therapies. Speaking of the 2019 full-year outlook, CSL’s Chief Executive Officer, Paul Perreault, previously remarked that:

‘CSL’s net profit after tax for FY19 would be in the range of approximately $1,880 to $1,950 million at constant currency. We now anticipate the profit figure to be around the upper end of this range.’

With good half-year results, and now an upgraded earnings outlook, investors will likely be keen to see CSL meet these increased expectations when the company reports its FY19 results next week.

Accordingly, the share price has the potential to come under pressure from investors in the wake of its full-year results if these expectations are not met.

Risks and analysts' estimates

Though CSL has guided profits higher for FY19, the company’s Seqirus product – an important influenza vaccine, has lagged.

Here the company flagged that while Seqirus:

‘Is tracking to plan but due to the seasonability of this business we anticipate it to post a loss in the second half of the fiscal year.'

Finally, though CSL trades ahead of the market – in terms of its price to earnings ratio – the biotechnology giant retains an overweight analyst consensus, according to the Wall Street Journal.

Of the 13 analysts covering the stock, seven rate it as a buy while six rate it as a sell.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.